Epigenetic Regulation of Exercise Induced Asthma

Status Recruiting

Clinical Trial Summary

The purpose of this study is to investigate the micro ribonucleic acid (mRNA) profiles of patients with EIA without allergic sensitization and EIA with house dust mite sensitization compared to that of healthy controls.

Clinical Trial Description

Patients with known EIA are periodically reexamined by medical history, clinical examination, bodyplethysmography, spirometry, exhaled nitric oxide (eNO), skin prick test, methacholin challenge test and exercise-challenge in a cold-chamber at 2-4°C (ECC). Additionally the investigators gathers the questionnaires: Asthma Control Test (ACT) and Dyspnoe Index (DI). Besides these standard procedures the investigators want to investigate the micro-RNA profiles in two EIA subgroups: EIA with house-dust allergy (n = 24) and EIA without house-dust allergy (n = 24). Both groups are characterized by different eNO levels. The patients with EIA and house-dust allergy should have an eNO > 30 ppb, the patients with EIA without house-dust allergy an eNO < 20 ppb. The micro-RNA profiles of the both EIA subgroups will be compared the micro RNA profiles of 20 healthy controls . Therefore blood will be taken (for a complete blood count and micro RNA analysis) at three points of time: before ECC, directly after ECC and after 24 hours ± 4 hours after ECC. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05174689
Study type	Interventional
Source	Johann Wolfgang Goethe University Hospital
Contact	Melanie Dreßler, MD
Phone	+49-69-6301-4588
Email	melanie.dressler@kgu.de
Status	Recruiting
Phase	N/A
Start date	August 1, 2021
Completion date	September 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02443805` - Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR	Phase 3
Completed	`NCT03094845` - Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients	Phase 2
Completed	`NCT01923792` - ToleroMune House Dust Mite Follow on Study	N/A
Completed	`NCT01930461` - Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma	Phase 2
Completed	`NCT00574704` - A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis	Phase 2
Completed	`NCT00263549` - Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis	Phase 4
Completed	`NCT05019209` - Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients	N/A
Recruiting	`NCT02238353` - AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)	Phase 4
Completed	`NCT01454544` - A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet	Phase 3
Terminated	`NCT01777464` - Role of the Central Nervous System in Allergic Rhinitis	N/A
Completed	`NCT00574223` - A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis	Phase 2
Completed	`NCT02345278` - SUBLIVAC FIX Mite Mixture Dose Tolerability Study	Phase 1/Phase 2
Completed	`NCT01608243` - Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts	Phase 1
Completed	`NCT04435678` - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens	N/A
Completed	`NCT01134757` - Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.	N/A
Recruiting	`NCT05395689` - Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM	Phase 3
Not yet recruiting	`NCT05400811` - Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis	Phase 3
Not yet recruiting	`NCT05450289` - The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy	N/A
Terminated	`NCT04874714` - Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis	Phase 3
Completed	`NCT00380926` - Fish Oil and Asthma in House Dust Mite Allergy	Phase 2/Phase 3